StockData

Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.96−0.10 (-1.24%)

Close on Nov 17, 2026Market cap $1.31BP/E –Yield –

Novavax price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Novavax's price to book ratio was 36.2× on Oct 31, 2025, against 12.8× a year earlier. Over the last 5 years it ranged from 3.5× to 130.6×, with a median of 8.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Oct 31, 202536.2×−29.0
2022Jul 29, 202265.2×+41.8
2021Dec 31, 202123.4×−42.5
2020Dec 31, 202065.9×+58.8
2017Jan 31, 20177.1×+0.3
2016Dec 30, 20166.9×+0.7
2015Dec 31, 20156.2×+0.8
2014Dec 31, 20145.4×+0.5
2013Dec 31, 20134.9×+0.8
2012Dec 31, 20124.1×+1.4
2011Dec 30, 20112.7×–

More Novavax figures

See a number that looks wrong?